John C. Davis
Direttore/Membro del Consiglio presso Rheos Medicines, Inc.
Profilo
John C.
Davis is currently a Director at Rheos Medicines, Inc., a Director at Sonoma Biotherapeutics, Inc., and a Non-Executive Director at Nucleome Therapeutics Ltd.
Previously, he held positions as a Senior Group Director at Genentech, Inc. from 2007 to 2015, Senior VP & Head-Early Clinical Development at Pfizer Inc. from 2016 to 2018, Vice President & Head-Global Therapeutic Area at Baxalta, Inc. in 2015, and Chief Medical Officer, Head-Research & Development at Magenta Therapeutics, Inc. from 2020 to 2021.
He also served as a Professor at The University of California, San Francisco.
Dr. Davis obtained a graduate degree from the University of California, Berkeley and the University of Maryland School of Medicine.
Posizioni attive di John C. Davis
| Società | Posizione | Inizio |
|---|---|---|
Rheos Medicines, Inc.
 Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | Direttore/Membro del Consiglio | 13/07/2021 |
Sonoma Biotherapeutics, Inc.
 Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA. | Direttore/Membro del Consiglio | 17/08/2022 |
Nucleome Therapeutics Ltd.
 Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nucleome Therapeutics Ltd. develops small molecular drugs for autoimmune diseases. The company was founded by Danuta Mariola Jeziorska, James Raymond Hughes and James Davies and is headquartered in Oxford, the United Kingdom. | Direttore/Membro del Consiglio | 25/04/2024 |
Precedenti posizioni note di John C. Davis
| Società | Posizione | Fine |
|---|---|---|
| MAGENTA THERAPEUTICS | Direttore Tecnico/Scientifico/R&S | 30/07/2021 |
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2018 |
| BAXALTA INC | Corporate Officer/Principal | 01/01/2016 |
| The University of California, San Francisco | Corporate Officer/Principal | 01/01/2015 |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2015 |
Formazione di John C. Davis
| University of California, Berkeley | Graduate Degree |
| University of Maryland School of Medicine | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | Health Technology |
Sonoma Biotherapeutics, Inc.
Sonoma Biotherapeutics, Inc. BiotechnologyHealth Technology Sonoma Biotherapeutics, Inc. provides research, development, and manufacturing capabilities in cell therapy and genetic engineering. The company was founded by Jeffrey A. Bluestone, Fred Ramsdell, Alexander Rudensky, and Qizhi Tang in 2019 and is headquartered in South San Francisco, CA. | Health Technology |
Nucleome Therapeutics Ltd.
Nucleome Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nucleome Therapeutics Ltd. develops small molecular drugs for autoimmune diseases. The company was founded by Danuta Mariola Jeziorska, James Raymond Hughes and James Davies and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- John C. Davis